A Study to Evaluate Preemptive Therapy in Hepatitis C Organ Transplant Recipients

Overview

About this study

The purpose of this study is to determine the effectiveness of using a combination of two different drugs in preventing the transmission of HCV from a HCV positive donor to a HCV negative solid organ recipient. Both drugs are FDA-approved. Mavyret™ is currently used commercially to treat Hepatitis C and Zetia® is used commercially to treat high cholesterol.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Listed kidney, heart, lung and/or pancreas patients who are negative for chronic hepatitis C infection.
  • Willing to accept and consent for accepting hepatitis C positive graft.

Exclusion Criteria:

  • Existing chronic liver disease (liver cirrhosis).
  • Concomitant infection with HIV or Chronic hepatitis B.
  • Patient or any member of patient family or care giver team who does not understand or accept the risk of an acquired HCV infection.
  • Pregnancy (pregnant patients do not undergo liver transplants).

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Jacksonville, Fla.

Mayo Clinic principal investigator

Surakit Pungpapong, M.D.

Closed for enrollment

Contact information:

Clinical Studies Unit

(904) 953-2255

Scottsdale/Phoenix, Ariz.

Mayo Clinic principal investigator

Bashar Aqel, M.D.

Closed for enrollment

Contact information:

Clinical Studies Unit

(904) 953-2255

More information

Publications

Publications are currently not available